Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Protagonist Therapeutics, Inc., Medpace Holdings or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Protagonist Therapeutics, Inc., Medpace Holdings and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Protagonist Therapeutics, Inc., Medpace Holdings and Inc.

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Latest Biotechnology and Protagonist Therapeutics, Inc., Medpace Holdings, Inc. Stock News

As of July 31, 2026, Protagonist Therapeutics, Inc. had a $8.8 billion market capitalization, compared to the Biotechnology median of $252.6 million. Protagonist Therapeutics, Inc.’s stock is up 56.4% in 2026, up 0.4% in the previous five trading days and up 150.17% in the past year.

Currently, Protagonist Therapeutics, Inc. does not have a price-earnings ratio. Protagonist Therapeutics, Inc.’s trailing 12-month revenue is $74.1 million with a -154.9% net profit margin. Year-over-year quarterly sales growth most recently was 99.3%. Analysts expect adjusted earnings to reach $4.467 per share for the current fiscal year. Protagonist Therapeutics, Inc. does not currently pay a dividend.

As of July 31, 2026, Medpace Holdings, Inc. had a $16.1 billion market cap, putting it in the 83rd percentile of all stocks. Medpace Holdings, Inc.’s stock is up 2.8% in 2026, down 4% in the previous five trading days and up 31.83% in the past year.

Currently, Medpace Holdings, Inc.’s price-earnings ratio is 33.8. Medpace Holdings, Inc.’s trailing 12-month revenue is $2.8 billion with a 17.7% net profit margin. Year-over-year quarterly sales growth most recently was 17.2%. Analysts expect adjusted earnings to reach $17.705 per share for the current fiscal year. Medpace Holdings, Inc. does not currently pay a dividend.

How We Compare Protagonist Therapeutics, Inc., Medpace Holdings and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Protagonist Therapeutics, Inc., Medpace Holdings and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Protagonist Therapeutics, Inc., Medpace Holdings and Inc. Growth Grades

Company	Ticker	Growth
Protagonist Therapeutics, Inc.	PTGX	D
Medpace Holdings, Inc.	MEDP	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Protagonist Therapeutics, Inc. has a Growth Score of 29, which is Weak. Medpace Holdings, Inc. has a Growth Score of 69, which is Strong.

The Growth Grade Winner: Medpace Holdings, Inc.

As you can clearly see from the Growth Grade breakdown above, Medpace Holdings, Inc. has a more attractive growth grade than Protagonist Therapeutics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Medpace Holdings, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Protagonist Therapeutics, Inc., Medpace Holdings and Inc.’s Momentum Grades

Company	Ticker	Momentum
Protagonist Therapeutics, Inc.	PTGX	A
Medpace Holdings, Inc.	MEDP	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Protagonist Therapeutics, Inc. has a Momentum Score of 94, which is Very Strong. Medpace Holdings, Inc. has a Momentum Score of 85, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Protagonist Therapeutics, Inc., Medpace Holdings and Inc. have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Protagonist Therapeutics, Inc., Medpace Holdings and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Protagonist Therapeutics, Inc.	PTGX	B
Medpace Holdings, Inc.	MEDP	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Protagonist Therapeutics, Inc. has a Earnings Estimate Score of 67, which is Positive. Medpace Holdings, Inc. has a Earnings Estimate Score of 63, which is Positive.

The Earnings Estimate Revisions Grade Winner: It’s a Tie!

Looking at the Earnings Estimate Revisions Grade breakdown above, both Protagonist Therapeutics, Inc., Medpace Holdings and Inc. have a grade of B. For those focusing solely on a company’s estimate revisions, other financial metrics will need to be evaluated to determine whether Protagonist Therapeutics, Inc., Medpace Holdings or Inc. is a better fit.

Other Protagonist Therapeutics, Inc., Medpace Holdings and Inc. Grades

In addition to Momentum, Estimate Revisions and Growth, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Protagonist Therapeutics, Inc., Medpace Holdings and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Protagonist Therapeutics, Inc., Medpace Holdings or Inc. Stock?

Overall, Protagonist Therapeutics, Inc. stock has a Growth Score of 29, Momentum Score of 94 and Estimate Revisions Score of 67.

Medpace Holdings, Inc. stock has a Growth Score of 69, Momentum Score of 85 and Estimate Revisions Score of 63.

Comparing Protagonist Therapeutics, Inc., Medpace Holdings and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.